Trial reportIntensive care medicine2010
Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.
Trial report in Intensive care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00534287 (Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem®) Versus a Combination Therapy With Moxifloxacin (Avalox®) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shock
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.Intensive care medicine · 2017Guideline
- A Review of High-Sensitivity SERS-Active Photonic Crystal Fiber Sensors for Chemical and Biological Detection.Sensors (Basel, Switzerland) · 2025Review
- The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review.Critical care (London, England) · 2024Article
- Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation.Acta pharmacologica Sinica · 2024Article
- The Prevalence, Risk Factors, and Outcomes of Sepsis in Critically Ill Patients in China: A Multicenter Prospective Cohort Study.Frontiers in medicine · 2020Article
- Calculated parenteral initial treatment of bacterial infections: Respiratory infections.GMS infectious diseases · 2020Article
- Rules of anti-infection therapy for sepsis and septic shock.Chinese medical journal · 2019Review
- Bacterial sepsis : Diagnostics and calculated antibiotic therapy.Der Anaesthesist · 2019Review
- Article
- Review
- [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Der Anaesthesist · 2017Review
- Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.Current infectious disease reports · 2015Article
- Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2015Article
- An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Virulence · 2014Review
- Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing.Intensive care medicine · 2013Article
- [Bacteremia and sepsis].Der Internist · 2013Article
- Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view.Intensive care medicine · 2011Review
- Year in review in Intensive Care Medicine 2010: II. Pneumonia and infections, cardiovascular and haemodynamics, organization, education, haematology, nutrition, ethics and miscellanea.Intensive care medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the steady-state pharmacokinetics of moxifloxacin in critically ill patients after intravenous administration of the 400 mg fixed dose.
methodsFifteen adult patients with severe sepsis (n = 3) or septic shock (n = 12) were enrolled in this dual-centre, prospective, open-label study. Moxifloxacin was administered with the recommended dose of 400 mg once daily i.v. for at least 5 days. Blood samples were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 and 24 h after the third administration. Moxifloxacin concentrations in plasma were measured by HPLC with fluorescence detection.
resultsData for 400 mg moxifloxacin i.v. were as follows (geometric mean): C (max): 3.5 mg/l, t(1/2): 7.8 h and AUC (48-72 h): 25 mg h/l. In five individual patients AUC (48-72 h) was <20 mg h/l.
conclusionThe main pharmacokinetics/pharmacodynamics parameter predicting clinical efficacy of moxifloxacin is AUC/MIC. The mean AUC of patients with severe sepsis or septic shock was lower compared to healthy volunteers (39 mg h/l). In 5 of 12 patients the AUC was halved compared to healthy volunteers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.